Standard

The future of pediatric hepatocellular carcinoma: A combination of surgical, locoregional, and targeted therapy. / Weeda, V. ola B.; Murawski, Maciej.

In: Hepatoma Research, Vol. 7, 43, 2021.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

APA

Vancouver

Author

BibTeX

@article{30f5b68a516b4db9b3ff71a57976822d,
title = "The future of pediatric hepatocellular carcinoma: A combination of surgical, locoregional, and targeted therapy",
abstract = "Despite hepatocellular carcinoma{\textquoteright}s position as the second most common pediatric liver tumor, it is a rare tumor in children warranting international collaboration to improve outcomes. Few cases diagnosed in earlier stages, when confined to the liver and responding to systemic treatment or with resectable metastases, may be cured by complete resection and/or orthotopic transplantation. Complete resection is the only chance for cure; therefore, all attempts should be made to make these options available. Despite modest progress in locoregional treatments, these serve in most cases as palliative treatment or as a bridge to definitive treatment at best. Currently used systemic treatments have response rates below 50%. Five-year survival in advanced stages is below 30%. The international Paediatric Hepatic International Tumour Trial trial is evaluating novel systemic treatments in pediatric hepatocellular carcinoma. Patients suffering from these tumors likely benefit from targeted treatment based on molecular aberrations corresponding with tumor subtype.",
keywords = "Hepatocellular carcinoma, Liver transplantation, Liver tumor, Locoregional treatment, Pediatric, Surgery, Targeted treatment",
author = "Weeda, {V. ola B.} and Maciej Murawski",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2021.",
year = "2021",
doi = "10.20517/2394-5079.2021.10",
language = "English",
volume = "7",
journal = "Hepatoma Research",
issn = "2394-5079",
publisher = "OAE Publishing Inc.",

}

RIS

TY - JOUR

T1 - The future of pediatric hepatocellular carcinoma: A combination of surgical, locoregional, and targeted therapy

AU - Weeda, V. ola B.

AU - Murawski, Maciej

N1 - Publisher Copyright: © The Author(s) 2021.

PY - 2021

Y1 - 2021

N2 - Despite hepatocellular carcinoma’s position as the second most common pediatric liver tumor, it is a rare tumor in children warranting international collaboration to improve outcomes. Few cases diagnosed in earlier stages, when confined to the liver and responding to systemic treatment or with resectable metastases, may be cured by complete resection and/or orthotopic transplantation. Complete resection is the only chance for cure; therefore, all attempts should be made to make these options available. Despite modest progress in locoregional treatments, these serve in most cases as palliative treatment or as a bridge to definitive treatment at best. Currently used systemic treatments have response rates below 50%. Five-year survival in advanced stages is below 30%. The international Paediatric Hepatic International Tumour Trial trial is evaluating novel systemic treatments in pediatric hepatocellular carcinoma. Patients suffering from these tumors likely benefit from targeted treatment based on molecular aberrations corresponding with tumor subtype.

AB - Despite hepatocellular carcinoma’s position as the second most common pediatric liver tumor, it is a rare tumor in children warranting international collaboration to improve outcomes. Few cases diagnosed in earlier stages, when confined to the liver and responding to systemic treatment or with resectable metastases, may be cured by complete resection and/or orthotopic transplantation. Complete resection is the only chance for cure; therefore, all attempts should be made to make these options available. Despite modest progress in locoregional treatments, these serve in most cases as palliative treatment or as a bridge to definitive treatment at best. Currently used systemic treatments have response rates below 50%. Five-year survival in advanced stages is below 30%. The international Paediatric Hepatic International Tumour Trial trial is evaluating novel systemic treatments in pediatric hepatocellular carcinoma. Patients suffering from these tumors likely benefit from targeted treatment based on molecular aberrations corresponding with tumor subtype.

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Liver tumor

KW - Locoregional treatment

KW - Pediatric

KW - Surgery

KW - Targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85114476569&partnerID=8YFLogxK

U2 - 10.20517/2394-5079.2021.10

DO - 10.20517/2394-5079.2021.10

M3 - Article

VL - 7

JO - Hepatoma Research

JF - Hepatoma Research

SN - 2394-5079

M1 - 43

ER -

ID: 19722494